MEDIPOST Launches Stem Cell Bank Establishment Service Using Domestically Developed Media
Launching in November... Commercializing government-funded project results to expand CDMO business
Uses Excel Therapeutics' chemically defined medium... Excludes animal-derived components
New service builds on results of MOTIE's MPE Top-tier Company project
MEDIPOST is expanding its contract development and manufacturing (CDMO) business by launching a service to establish stem cell banks using domestically developed chemically defined media.
MEDIPOST said on October 28 that it will launch in November a service to establish stem cell banks using domestically developed chemically defined media free of animal-derived components (AOF). The service is aimed at companies developing cell and gene therapies (CGT).
Promotional image for MEDIPOST's stem cell banking service based on domestically developed chemically defined media. MEDIPOST
View original imageA cell bank is a system for storing and managing cells used in the development and production of cell and gene therapies while maintaining consistent quality. Ensuring the safety and uniformity of cells during cell bank establishment is important for quality control in subsequent research and development and production processes. AOF technology is an approach to reducing potential contamination risks associated with the use of animal-derived components.
The service uses CellCor™, a chemically defined medium developed by Excel Therapeutics, a company specializing in culture media. Chemically defined media have clearly specified types and quantities of chemical components. This medium is characterized by the exclusion of animal- and human-derived materials. It was also used as a domestically developed medium replacement in the Japan commercialization project for MEDIPOST's stem cell therapy product Cartistem.
The two companies have been jointly validating chemically defined media since 2020. In 2023, MEDIPOST was selected for a government-funded project related to the Ministry of Trade, Industry and Energy's Materials, Parts and Equipment (MPE) Top-tier Company program, and continued its technology development.
The service is available for umbilical cord blood-, umbilical cord- and adipose-derived stem cells, among others. Cell banks are divided into master cell banks and working cell banks used in manufacturing and production. MEDIPOST plans to support the establishment of customized cell banks by adjusting fill specifications, including vial volume and cell count, to meet client requirements.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An Excel Therapeutics representative said, "The adoption of chemically defined media is an essential trend in global CGT development. Through our partnership with MEDIPOST, we will become a total-solution company covering the entire CGT development lifecycle, backed by high safety and uniformity." A MEDIPOST representative said, "Our domestically developed chemically defined media service, which excludes animal-derived components, will help clients ensure safety and uniformity. By combining our GMP expertise with Excel Therapeutics' media technology, we will become a trusted partner to CGT companies in Korea and abroad."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
